Phase 2 ARDA Findings Support Development of Empasiprubart in Multifocal Motor Neuropathy
CIDP Agent Riliprubart Reduces Neurofilament Light in Phase 2 Subanalysis
Tanruprubart Shows Early, Sustained Quality-of-Life Improvements in Phase 3 GBS Trial
NeurologyLive® Brain Games: May 18, 2025